These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26257651)

  • 21. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
    Calabrese CR; Batey MA; Thomas HD; Durkacz BW; Wang LZ; Kyle S; Skalitzky D; Li J; Zhang C; Boritzki T; Maegley K; Calvert AH; Hostomsky Z; Newell DR; Curtin NJ
    Clin Cancer Res; 2003 Jul; 9(7):2711-8. PubMed ID: 12855651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways.
    Moro H; Hattori N; Nakamura Y; Kimura K; Imai T; Maeda M; Yashiro M; Ushijima T
    Gastric Cancer; 2020 Jan; 23(1):105-115. PubMed ID: 31555951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single Protein Encapsulated SN38 for Tumor-Targeting Treatment.
    Yu CJ; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
    Res Sq; 2023 Jul; ():. PubMed ID: 37546894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells.
    Ryu H; Choi HK; Kim HJ; Kim AY; Song JY; Hwang SG; Kim JS; Kim DU; Kim EH; Kim J; Ahn J
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
    Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
    Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
    Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
    Mans DR; Grivicich I; Peters GJ; Schwartsmann G
    Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
    Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
    BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38.
    Warren NJH; Donahue KL; Eastman A
    ACS Pharmacol Transl Sci; 2019 Jun; 2(3):168-182. PubMed ID: 32259055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair.
    Croglio MP; Haake JM; Ryan CP; Wang VS; Lapier J; Schlarbaum JP; Dayani Y; Artuso E; Prandi C; Koltai H; Agama K; Pommier Y; Chen Y; Tricoli L; LaRocque JR; Albanese C; Yarden RI
    Oncotarget; 2016 Mar; 7(12):13984-4001. PubMed ID: 26910887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
    Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
    Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
    Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
    Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
    Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
    Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
    Ariumi Y; Turelli P; Masutani M; Trono D
    J Virol; 2005 Mar; 79(5):2973-8. PubMed ID: 15709017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
    Pavillard V; Formento P; Rostagno P; Formento JL; Fischel JL; Francoual M; Etienne MC; Milano G
    Biochem Pharmacol; 1998 Nov; 56(10):1315-22. PubMed ID: 9825730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
    Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
    BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.